Mallinckrodt plc – AMEX:MNK
Mallinckrodt stock price today
$0.351
+0.01
+3.03%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Mallinckrodt stock price monthly change
-73.85%
month
Mallinckrodt stock price quarterly change
-88.44%
quarter
Mallinckrodt key metrics
Market Cap | 4.52M |
Enterprise value | 2.75B |
P/E | -0.76 |
EV/Sales | 1.43 |
EV/EBITDA | -7.69 |
Price/Sales | 0.03 |
Price/Book | 0.03 |
PEG ratio | -0.03 |
EPS | -120.86 |
Revenue | 1.93B |
EBITDA | 177.4M |
Income | -1.59B |
Revenue Q/Q | 23.79% |
Revenue Y/Y | -2.00% |
Profit margin | -47.6% |
Oper. margin | -18.48% |
Gross margin | 17.83% |
EBIT margin | -18.48% |
EBITDA margin | 9.15% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMallinckrodt stock price history
Mallinckrodt stock forecast
Mallinckrodt financial statements
| Sep 2022 | 465.4M | -285.3M | -61.3% |
|---|---|---|---|
| Dec 2022 | 574.3M | -313M | -54.5% |
| Mar 2023 | 424.6M | -249.3M | -58.71% |
| Jun 2023 | 475M | -747.8M | -157.43% |
| Sep 2022 | 6257400000 | 4.40B | 70.45% |
|---|---|---|---|
| Dec 2022 | 6013800000 | 4.40B | 73.17% |
| Mar 2023 | 5770800000 | 4.40B | 76.36% |
| Jun 2023 | 5106900000 | 4.48B | 87.75% |
| Sep 2022 | 19.3M | 49.6M | -17.3M |
|---|---|---|---|
| Dec 2022 | 27.8M | -22.1M | -36.8M |
| Mar 2023 | 99.9M | -19M | -11M |
| Jun 2023 | 21.1M | -6.6M | -11.1M |
Mallinckrodt alternative data
| Aug 2023 | 2,673 |
|---|---|
| Sep 2023 | 2,673 |
| Oct 2023 | 2,673 |
| Nov 2023 | 2,673 |
| Dec 2023 | 2,673 |
| Jan 2024 | 2,673 |
| Feb 2024 | 2,673 |
| Mar 2024 | 2,673 |
| Apr 2024 | 2,673 |
| May 2024 | 2,673 |
| Jun 2024 | 2,673 |
| Jul 2024 | 2,673 |
Mallinckrodt other data
43.01%
-35.43%
of MNK is owned by hedge funds
24
-22
5.67M
-4.67M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 40133 | 0 |
| Dec 2023 | 75000 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 28 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 8 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
What's the price of Mallinckrodt stock today?
One share of Mallinckrodt stock can currently be purchased for approximately $0.35.
-
When is Mallinckrodt's next earnings date?
Unfortunately, Mallinckrodt's (MNK) next earnings date is currently unknown.
-
Does Mallinckrodt pay dividends?
No, Mallinckrodt does not pay dividends.
-
How much money does Mallinckrodt make?
Mallinckrodt has a market capitalization of 4.52M.
-
What is Mallinckrodt's stock symbol?
Mallinckrodt plc is traded on the AMEX under the ticker symbol "MNK".
-
What is Mallinckrodt's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Mallinckrodt?
Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Mallinckrodt have?
As Jul 2024, Mallinckrodt employs 2,673 workers.
-
When Mallinckrodt went public?
Mallinckrodt plc is publicly traded company for more then 3 years since IPO on 21 Jun 2022.
-
What is Mallinckrodt's official website?
The official website for Mallinckrodt is mallinckrodt.com.
-
How can i contact Mallinckrodt?
Mallinckrodt can be reached via phone at +353 1 696 0000.
Mallinckrodt company profile:
Mallinckrodt plc
mallinckrodt.comExchange:
AMEX
Full time employees:
2,673
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
College Business & Technology Park
Dublin, 15
Dublin, 15
CIK: 0001567892
:
:
